Full Name
Dent, R.A.
Variants
Dent, R.
Dent, R.A.
 
 
Email
gmsrad@nus.edu.sg
 

Publications

Results 1-11 of 11 (Search time: 0.008 seconds).

Issue DateTitleAuthor(s)
12015A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22Trudeau, M.E; Chapman, J.-A.W; Guo, B; Clemons, M.J; Dent, R.A ; Jong, R.A; Kahn, H.J; Pritchard, K.I; Han, L; O’Brien, P; Shepherd, L.E; Parissenti, A.M
22016Barriers and facilitators for clinical trial participation among diverse Asian patients with breast cancer: A qualitative studyLee, G.E; Ow, M ; Lie, D ; Dent, R 
32018Cost of Medical Care of Patients with Advanced Serious Illness in Singapore (COMPASS): Prospective cohort study protocolTeo, I ; Singh, R; Malhotra, C ; Ozdemir, S ; Dent, R.A ; Kumarakulasinghe, N.B; Yeo, W.L; Cheung, Y.B ; Malhotra, R ; Kanesvaran, R ; Yee, A.C.P ; Chan, N ; Wu, H.Y; Chin, S.M; Allyn, H.Y.M; Yang, G.M ; Neo, P.S.H ; Nadkarni, N.V ; Harding, R; Finkelstein, E.A 
42018Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancersYap, Y.-S; Singh, A.P; Lim, J.H.C; Ahn, J.-H; Jung, K.-H; Kim, J; Dent, R.A ; Ng, R.C.H ; Kim, S.-B; Chiang, D.Y
52018High densities of tumor-associated plasma cells predict improved prognosis in triple negative breast cancerYeong J.; Lim J.C.T.; Lee B.; Li H. ; Chia N.; Ong C.C.H.; Lye W.K. ; Putti T.C. ; Dent R. ; Lim E. ; Thike A.A. ; Tan P.H. ; Iqbal J. 
61-Jun-2011In situ DNA repair assays as guides to personalized breast cancer chemotherapeutics: Ready for prime time?Dent, R.A. ; Bristow, R.G.
72014Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: Cognitive function (FACT-Cog) in breast cancer patientsCheung, Y.T.; Foo, Y.L.; Shwe, M.; Tan, Y.P.; Fan, G.; Yong, W.S.; Madhukumar, P.; Ooi, W.S.; Chay, W.Y.; Dent, R.A. ; Ang, S.F.; Lo, S.K.; Yap, Y.S.; Ng, R. ; Chan, A. 
82013Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancerDent, R.A ; Lindeman, G.J; Clemons, M; Wildiers, H; Chan, A; McCarthy, N.J; Singer, C.F; Lowe, E.S; Watkins, C.L; Carmichael, J
92012Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancerByrski, T; Dent, R ; Blecharz, P; Foszczynska-Kloda, M; Gronwald, J; Huzarski, T; Cybulski, C; Marczyk, E; Chrzan, R; Eisen, A; Lubinski, J; Narod, S.A
10Sep-2012Targeting triple-negative breast cancer: Optimising therapeutic outcomesGelmon, K.; Dent, R. ; Mackey, J.R.; Laing, K.; Mcleod, D.; Verma, S.
112015Trends in presentation, management and survival of patients with de novo metastatic breast cancer in a Southeast Asian settingBhoo-Pathy, N; Verkooijen, H.M ; Tan, E.-Y; Miao, H ; Taib, N.A.M; Brand, J.S; Dent, R.A ; See, M.-H; Subramaniam, S; Chan, P ; Lee, S.-C; Hartman, M ; Yip, C.-H